Breet's Enhancement Addresses Africa's Cryptocurrency Instability and Delayed Transactions
- Breet 3.0 Pro Max upgrades Africa's OTC crypto platform with USD wallets, instant transfers, and flat fees to combat volatility and slow settlements. - Key features include stable dollar holdings, peer-to-peer transfers bypassing banks , and automated issue resolution to reduce transaction friction. - Business tools now offer multi-currency templates, VIP tiers for high-volume traders, and security dashboards tracking account activity. - The update addresses Africa's crypto challenges by stabilizing purc
Breet, a prominent OTC crypto platform in Africa, has unveiled Breet 3.0 Pro Max, a significant update aimed at simplifying crypto-to-cash exchanges and tackling persistent issues in digital asset handling throughout the continent.
This version brings in the option to store converted crypto as stable dollars, letting users keep their funds in stable dollars before exchanging them for local currencies at favorable rates.
For business users, Breet now offers enhanced
This upgrade tackles major challenges in Africa’s crypto sector, where users have often dealt with slow payments, unstable values, and a lack of transparency
Breet’s CEO underscored the importance of this release in a November 22 statement, saying, "
The platform’s growth coincides with the rising use of crypto across Africa, where digital currencies are playing a bigger role in cross-border commerce, remittances, and business activities.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Solana News Update: Sunrise Seeks to Resolve Solana's Liquidity Splintering through Immediate Listings
- Wormhole Labs launches Sunrise, a Solana-native listing platform enabling instant liquidity for new tokens like MON, addressing DeFi fragmentation. - The platform uses NTT framework to natively onboard cross-chain assets, retaining liquidity within Solana and integrating with DEXs like Orb and Jupiter. - MON's day-one trading demonstrates Sunrise's potential to solidify Solana as a hub for tokenized assets, with TVL rising 32.7% to $11.5B in Q3 2025. - Analysts highlight Sunrise's role in standardizing h

India’s Cryptocurrency Conundrum: Can Updated VDA Regulations Safeguard Progress or Hinder Expansion?
- India's VDA regulatory review aims to align crypto rules with global standards, addressing consumer protection gaps and market integrity risks. - Current fragmented regulations, including 30% profit tax and weak custody laws, have driven users to offshore platforms, stifling local innovation. - Proposed reforms include risk-based token classification, licensing for exchanges, and RWA frameworks to balance innovation with systemic risk mitigation. - A balanced approach could attract investment and strengt

Bitcoin Updates Today: Bearish Pressure Mounts, Yet Optimistic Bulls Anticipate Future Expansion
- Bitcoin's bearish technical indicators reinforce downward pressure despite short-term recovery attempts. - Ethereum and altcoins mirror Bitcoin's weakness, with $2B in crypto liquidations intensifying selling pressure. - Long-term fundamentals project $17.14B crypto market growth by 2033 driven by institutional adoption and regulatory clarity. - Thailand's Bitkub plans $200M Hong Kong IPO amid local market struggles, highlighting regional listing strategy shifts. - Persistent bearish momentum remains, wi

Biomarkers Shine, Results Disappoint: Novo's Attempt at Alzheimer's Falls Short
- Novo Nordisk's Alzheimer's trials for semaglutide failed to meet primary endpoints, causing a 9% premarket stock drop to a multi-year low. - The $3.8B trial showed no disease progression slowing despite biomarker improvements, with UBS estimating only 10% success probability beforehand. - Market ripple effects included Eli Lilly's 0.5% decline and Biogen's 2.7% rise, highlighting GLP-1 drug competition in neurodegenerative therapies. - This setback compounds Novo's challenges: 50% YTD stock decline, obes
